Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911118 | Lung Cancer | 2014 | 7 Pages |
Abstract
Treatment with liposomal non-pegylated doxorubicin and ifosfamide could be a reasonable option in pleuropulmonary angiosarcoma but it should be validated in clinical trials. Chronic pyothorax seems to be a predisposing factor for the development of pleural angiosarcoma but further investigations are required to assess a causal association.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gema Bruixola, Robert DÃaz-Beveridge, Enrique Jiménez, Javier Caballero, Miguel Salavert, Corina Escoin, Jorge Aparicio,